These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19289350)

  • 21. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
    van Winkel R; De Hert M; Wampers M; Van Eyck D; Hanssens L; Scheen A; Peuskens J
    J Clin Psychiatry; 2008 Mar; 69(3):472-9. PubMed ID: 18348593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
    Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine.
    Tanaka K; Morinobu S; Ichimura M; Asakawa A; Inui A; Hosoda H; Kangawa K; Yamawaki S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1527-32. PubMed ID: 18571822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.
    Zhang C; Fang X; Yao P; Mao Y; Cai J; Zhang Y; Chen M; Fan W; Tang W; Song L
    Psychoneuroendocrinology; 2017 Jul; 81():138-143. PubMed ID: 28477447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
    Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
    J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Olanzapine and diabetic decompensation: concerning a case].
    Barceló Colomer ME; Mateu Ramon MC; Miralles Belda V; Moretó Reventós A
    Aten Primaria; 2004 Jun; 34(1):58-9. PubMed ID: 15207204
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder.
    Davis LL; Cates ME; Lowe JS; Ward LC; Johnson JD; Williford RB; Ambrose SM; Thomas BL; Kashner TM
    Psychopharmacol Bull; 2008; 41(1):85-98. PubMed ID: 18362873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
    Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.
    Lee CT; Conde BJ; Mazlan M; Visanuyothin T; Wang A; Wong MM; Walker DJ; Roychowdhury SM; Wang H; Tran PV
    J Clin Psychiatry; 2002 Jul; 63(7):569-76. PubMed ID: 12143912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.
    Dunlop BW; Sternberg M; Phillips LS; Andersen J; Duncan E
    Psychopharmacol Bull; 2003; 37(3):99-117. PubMed ID: 14608243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study.
    Novick D; Haro JM; Suarez D; Marques-Teixeira J; Naber D
    Int Clin Psychopharmacol; 2008 Jul; 23(4):203-8. PubMed ID: 18545058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics.
    Lu Z; Hu J; Chen CK; Lan TH; Diokno GL; Lee BY; McElroy H; Harrison G; Ang Q
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):32-40. PubMed ID: 16843580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
    Meyer JM
    J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
    Kreyenbuhl J; Slade EP; Medoff DR; Brown CH; Ehrenreich B; Afful J; Dixon LB
    Schizophr Res; 2011 Sep; 131(1-3):127-32. PubMed ID: 21576008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
    Guina J; Roy S; Gupta A; Langleben DD; Elman I
    Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
    Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.
    Peuskens J; De Hert M; Mortimer A;
    Int Clin Psychopharmacol; 2007 May; 22(3):145-52. PubMed ID: 17414740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.